Global Report of Cancer Biomarker Testing Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2016 and Forecast 2017-2024

28/mag/2018 09:26:31 sravan Contatta l'autore

Global Report of Cancer Biomarker Testing Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2016 and Forecast 2017-2024

 

Global Cancer Biomarker Testing Market:

Biomarker testing also known as genetic testing or molecular testing are group of tests that look for these molecular signs of health so that doctors can plan best care. Biomarker is any of body’s molecules that can be measured to assess the health. Molecules can be obtained from, body fluids, tissue or blood. Cancer biomarker is a process or substance that indicates the presence of cancer in the body as abnormal growth of cells. Genetic, epigenetic, glycemic, proteomic, and imaging biomarkers are used for cancer diagnosis, prognosis, and epidemiology. These cancer biomarkers used as risk indicators for various types of cancer such as lung cancer, breast cancer and prostate cancer among the others. 

 

The number of new cases is expected to rise about 70% over the coming 2 decades. In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO’s funding for oncology are expected to grow the cancer biomarker testing market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market.

 

Free sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-cancer-biomarker-testing-market/#ulp-4H8Z4LpNMLEuOnnx

 

The cancer biomarker testing market is categorized on the basis of-

1.      Type of cancer

·         Cervical cancer

·         Lung Cancer

·         Collateral Cancer

·         Liver Cancer

·         Prostate Cancer

·         Breast Cancer

·         Others

2.     Applications

·         Drug Discovery and Development

·         Personalized Medicine

·         Diagnosis

·         Others

3.     End-users

Hospitals, Cancer diagnostic centers, research institutes and others.

 

Free TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-cancer-biomarker-testing-market/#ulp-c654SbFYO64MsOhu

 

And lastly on the basis of geographical regions, the global cancer biomarker testing market have five major regions- North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is a major market due to increase in R & D activities for diagnosis and treating cancer and rise in prevalence of cancer. Asia-Pacific cancer biomarker test market is expected to be fastest growing market due to increase in demand for the non-invasive techniques in diagnosis and prevention of cancer, high prevalence of cancer conditions in the region.

 

Some of the players in cancer biomarker test market are Thermo Fisher Scientific (Affymetrix Inc.) (U.S.), Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (U.S.), Arquer Diagnostics Ltd. (U.K.), Illumina, Inc. (U.S.), Qiagen (Germany), Agilent Technologies (U.S.), Merck & Co. Inc. (U.S.), Becton Dickinson and Company (U.S.), and Hologic Inc. (U.S.) to name a few. In 2015, Abbot Laboratories acquired exclusive rights for FGFR3 gene mutations to detect bladder cancer. It is a gene mutation and useful for early detection, disease monitoring, and prognosis of bladder cancer through tissue and urine-based testing.

 

Ask Analyst for Full Information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-cancer-biomarker-testing-market/#ulp-14mlyhjMGhVjZqa3

 

Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share. For instance, in March 2017, Foundation Medicine and Bristol-Myers Squibb entered collaboration to understand tumor profile and its microenvironment to predict patient’s response to cancer immunotherapy. Key cancer biomarkers include SCC, CEA, NSE Cyfra 21, PSA (prostate cancer), TPA (Lung cancer), CA15-3, EGF R, Cytokeratin 4 (breast cancer) and BRCA ½.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-cancer-biomarker-testing-market/

 

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US):+1-866-598-1553

Website @https://www.precisionbusinessinsights.com

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl